

# **Metabolic Reprogramming to Improve Immunotherapy**

**Kevin Howcroft**

**Cancer Immunotherapy and Hematology Branch  
Division of Cancer Biology**

**Dinah Singer**


**Division of Cancer Biology**

## Metabolic Reprogramming to Improve Immunotherapy


**The overall goals of this concept are to:**

- **generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses *in vivo***
- **determine how the metabolic landscape of the tumor microenvironment affects immune effector functions**
- **use this information to manipulate (or reprogram) the metabolic pathways used by the tumor, the effectors of the immune response, or both to improve cancer immunotherapy**


# Cancer Cells Reprogram Metabolism to Support Growth and Survival




# Activated Immune Cells Undergo Metabolic Reprogramming



# Tumor Metabolic Landscapes can Regulate Anti-Tumor Immune Function



# Tumor Metabolic Landscapes can Regulate Anti-Tumor Immune Function



**Hypothesis:**  
**Metabolic manipulation might be able to skew immune responses to enhance T cell responses and immunotherapy.**

## Address Knowledge Gap and Path Forward

### Overarching Directions for Future Studies:

- a) Approaches to reprogram the metabolism of anti-tumor immune cells (either *ex vivo* or *in vivo*) to improve immunotherapy (homing, effector function, and/or persistence)
- b) Approaches to target cancer cell metabolism to impair cancer cell survival without compromising anti-tumor immunity.

### Path Forward:

- Catalyze collaborations between tumor immunologists, cancer biologists, computational modelers and tool/technology specialists aimed at developing innovative approaches to utilize metabolic reprogramming to improve cancer immunotherapy.

## Specific Challenges

### Examples :

- How do the metabolic environments in normal tissues, immune tissues, and tumors affect immune cell development and/or effector function?
- How do specific metabolites affect various immune states such as activation, anergy, development of long-lived memory cells versus short-lived effector cells, and homing to their proper niche?
- Do metabolites act as signaling molecules in transcription that effect cellular differentiation?

# Implementation Plan

**Goal: Encourage new collaborations focused on tumor immunometabolism**

**Mechanism:**

- **Supplement existing NCI funded grants to support collaborative research projects through revision applications (formerly called competing supplements).**

**Funding Opportunity:**

- **PAR with no budget set-aside.**
- **Standard Receipt Dates; beginning March, 2014.**
- **Active in FY15 - FY18.**


## Examples of Collaborations

- **A cancer biologist with an existing NCI RO1 focused on cancer cell metabolism could form a collaboration with a tumor immunologist and a systems biologist to develop computational models of metabolic interactions**
- **A tumor immunologist with an existing NCI RO1 focused on metabolic events associated with activated T cells could form a collaboration with a cancer biologist studying metabolism and with an in vivo imager to study homing.**

## Collaboration Criteria

- **Must propose cross-disciplinary research involving cancer biologists and immunologists aimed at complementary areas of metabolic research and, if justified, a metabolomics, computational tools, or imaging component.**
- **May support up to three collaborating groups, including the PI of the parent grant**
- **Must be complementary to the parent grant**
- **Must have a minimum of two years remaining on the parent grant at the time of award**

# Tumor Metabolic Landscapes can Regulate Anti-Tumor Immune Function



# Questions?

## Portfolio Analysis

**Searching the NIH Reporter for applications that cross reference the terms immunotherapy, metabolism, and cancer netted only five applications that would minimally meet the outlines of this FOA - only one R21 specifically included metabolic reprogramming of immune cell populations to improve immunotherapy.**

## NCI/DCB Activities to Promote Research Collaborations (APRC) 1998-2010

- The APRC program supported new interdisciplinary collaborations to bridge disparate fields and expand the pool of scientists working in cancer research.
- The APRC provided administrative supplements to support 2-3 collaborating units (from complementary fields) focused on achieving specific research objectives by pooling their respective expertise and efforts.
- Funding decisions were made rapidly, allowing collaborations to initiate quickly.
- The annual allocation to DCB for the program was \$1-1.5M. Over the years, it funded 437 collaborations, with a peak in 2004 of 85 consortia.
- An independent evaluation after the conclusion of the APRC assessed its success. Among the conclusions: “ Most impressive, the majority of the investigators thought that they could not have accomplished their work without APRC funding.”

